Golden Valley Development Inc. announced a purchase order agreement and strategic partnership with Mel-Mont Medical, LLC, to commercialize XytoTest(TM) worldwide. The purchase order agreement entails the initial purchase by Mel-Mont of 100,000 XytoTest(TM) units from GVDI valued at $440,000 and to be delivered in 4 equal phases with larger commercial orders to follow. The product is being clinically tested in Spain, Columbia, and has a clear path for commercialization in 31 countries in Europe through the CE registration.

XytoTest(TM) is in the process of obtaining the necessary approvals from Mexico and US FDA. It is covered by a US Patent PTO number 62045844. XytoTest(TM) is a self-sampling kit of cervical specimens for the analysis of DNA for the 14 high-risk strains of HPV (Human Papilloma Virus).

The medical device is comprised of a hollow sheath made of special resin that meets US FDA 21 CFR 181.32 requirements. The device is user-friendly and is less than 8 millimeters in diameter. There is a cell collector of USP medical grade IV elastomer fully tested to guarantee no skin or mucous membrane irritation in accordance to ISO 10993-5 and ISO 10993-10.